explore -WSS

explore

author：Wikipedia 2025-09-03 05:32:50 - browse：1

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： AstraZeneca lung cancer study comes in below expectations

WSS

Fatty liver disease was alleviated by Lilly’s ‘triple

Woman returns to dialysis after doctors remove transplanted pig kidney

With trial win, GSK could get blood cancer drug back on market

How to increase colonoscopy rates? Looks like an AI can help

Woman returns to dialysis after doctors remove transplanted pig kidney

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

explore

The contrarian view of Viking Therapeutics

focus

How one medical school became remarkably diverse

Prescription digital therapeutics are key to pharma’s future

Novavax promises a turnaround & Lilly roils the obesity market

Fatty liver disease was alleviated by Lilly’s ‘triple

Virginia high school admissions case could be legal follow

Woman returns to dialysis after doctors remove transplanted pig kidney

Hollywood unions extend contract negotiations for actors

Fatty liver disease was alleviated by Lilly’s ‘triple

How to save PrEP access — and even expand it

Canadians with cystic fibrosis outlive Americans by a decade

hotspot

Letters to First Opinion on caregivers, digital health, and more

How to increase colonoscopy rates? Looks like an AI can help

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

AstraZeneca lung cancer study comes in below expectations

Cord blood banking comes at a high cost to babies

focus

entertainment

knowledge

focus